Cargando…
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 vaccine in patients with CLL. We evaluated humoral immune responses to the BNT162b2 messenger RNA (mRNA) COVID-19 vaccin...
Autores principales: | Herishanu, Yair, Avivi, Irit, Aharon, Anat, Shefer, Gabi, Levi, Shai, Bronstein, Yotam, Morales, Miguel, Ziv, Tomer, Shorer Arbel, Yamit, Scarfò, Lydia, Joffe, Erel, Perry, Chava, Ghia, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061088/ https://www.ncbi.nlm.nih.gov/pubmed/33861303 http://dx.doi.org/10.1182/blood.2021011568 |
Ejemplares similares
-
Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia
por: Herishanu, Yair, et al.
Publicado: (2022) -
Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells
por: Shorer Arbel, Yamit, et al.
Publicado: (2021) -
PB2288: INCIDENCE OF NEWLY DIAGNOSED AGGRESSIVE NON-HODGKIN’S LYMPHOMA BEFORE AND DURING THE COVID-19 PANDEMIC IN ISRAEL - A SINGLE CENTER RETROSPECTIVE STUDY
por: Bronstein, Yotam, et al.
Publicado: (2023) -
Spatial organization and early signaling of the B-cell receptor in CLL
por: Shorer Arbel, Yamit, et al.
Publicado: (2022) -
REGEN‐COV antibody combination in patients with lymphoproliferative malignancies and SARS‐CoV‐2 infection
por: Bronstein, Yotam, et al.
Publicado: (2022)